Skip to main content

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

  • U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes
  • Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously
  • The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R)
  • Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year
  • The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in pre-clinical testing against immunotherapy-resistant tumors, reporting success with a different gene than the one in use for the Fast Tracked programs, thus showing early viability for the use of the Oncoprex platform with a second tumor suppressor gene
  • Genprex’s chief medical officer discusses the developments in a new video released by the company May 23

Clinical-stage gene therapy developer Genprex (NASDAQ: GNPX) is expanding the breadth of its drug candidate potential with positive results from a preclinical study that examines the anti-tumor immune response of a gene believed to play a key role in suppressing certain tumors.

Genprex’s lead drug candidate, REQORSA immunogene therapy, uses Genprex’s proprietary, non-viral ONCOPREX Nanoparticle Delivery System to introduce the tumor-suppressing TUSC2 gene through an…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.